Breaking News, Trials & Filings

Gazyva Wallops Rituxan in CLL Trial

Extends PFS by nearly 12 months

By: Gil Roth

President, Pharma & Biopharma Outsourcing Association

Genentech/Roche has posted new data from the second stage of its Phase III CLL11 study. This study conducted in cooperation with the German CLL Study Group, compared Gazyva (obinutuzumab) in combination with chlorambucil to Rituxan (rituximab) in combination with chlorambucil for people with previously untreated chronic lymphocytic leukemia (CLL) and co-existing medical conditions. The data showed that people treated in the Gazyva arm lived nearly a year longer without their disease worsening (p...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters